这项研究发现人类记忆性B细胞所主要使用的IgG1型抗原受体（IgG1-BCR）膜联重链的胞内信号转导区ITT-Tyr下游正五位的G396R变异体（rs117518546，IgG1-G396R ...

How do antibody engineers select isotypes? IgG1 has been the most popular choice by far and was used for 13 approved chimeric, humanized or fully human antibodies (compared with only two instances ...

这项研究发现人类记忆性B细胞所主要使用的IgG1型抗原受体（IgG1-BCR）膜联重链的胞内信号转导区ITT-Tyr下游正五位的G396R变异体（rs117518546，IgG1-G396R）在东南亚中南半岛为主的周边地区人群呈现超高频分布，并能增强针对危险致命生物的IgG1型抗体防护反应。

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

Rituximab is a chimeric IgG1 monoclonal antibody created by fusing the light and heavy chain variable domains of 2B8, a murine monoclonal anti-CD20 antibody, and human α-light chain and γ1-heavy ...

Rationale To date, the exact significance of esophageal eosinophilia requires careful clinical consideration. Traditionally, this finding has been attributed solely to peptic injury, but with the ...

The US Food and Drug Administration (FDA) has rejected the Biologics License Application (BLA) of Astellas Pharma’s zolbetuximab for gastric cancer on grounds of third-party manufacturing concerns.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SYRACUSE, N.Y.--(BUSINESS WIRE)--Chimera Integrations, a security systems integrator known for its innovative and solutions-based approach, is proud to announce that it has been named SDM's 2024 ...

Soil gently brushed off an ancient piece of pottery, paint peeling from a villa wall, a hand stroking the white, marble face of a statue unseen for thousands of years: La Chimera is a tactile ...

Chimera Investment Corporation is a specialty finance company that invests, either directly or indirectly through its subsidiaries, in residential mortgage-backed securities (RMBS), residential ...

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New ...